P
Philippe Moreau
Researcher at University of Nantes
Publications - 693
Citations - 52995
Philippe Moreau is an academic researcher from University of Nantes. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 104, co-authored 517 publications receiving 42530 citations. Previous affiliations of Philippe Moreau include University of Grenoble & National and Kapodistrian University of Athens.
Papers
More filters
Journal ArticleDOI
Chemotherapy‐driven dysbiosis in the intestinal microbiome
Emmanuel Montassier,Emmanuel Montassier,Thomas Gastinne,Pajau Vangay,Gabriel A. Al-Ghalith,S. Bruley des Varannes,Sébastien Massart,Philippe Moreau,Gilles Potel,M. F. de La Cochetière,Eric Batard,Dan Knights +11 more
TL;DR: Chemotherapy is commonly used as myeloablative conditioning treatment to prepare patients for haematopoietic stem cell transplantation (HSCT) and current models of GI mucositis pathophysiology are generally silent on the role of the intestinal microbiome.
Journal ArticleDOI
Thalidomide for treatment of multiple myeloma: 10 years later
Antonio Palumbo,Thierry Facon,Pieter Sonneveld,Joan Bladé,Massimo Offidani,Philippe Moreau,Anders Waage,Andrew Spencer,Heinz Ludwig,Mario Boccadoro,Jean-Luc Harousseau +10 more
TL;DR: In elderly, newly diagnosed patients, 3 independent randomized studies have reported that the oral combination of melphalan and prednisone plus thalidomide (MPT) is better than the standard melphAlan and predisonsone (MP) and 2 have shown improved overall survival for patients assigned to MPT.
Journal ArticleDOI
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.
Michele Cavo,S. Vincent Rajkumar,Antonio Palumbo,Philippe Moreau,Robert Z. Orlowski,Joan Bladé,O. Sezer,Heinz Ludwig,Meletios A. Dimopoulos,Michel Attal,Pieter Sonneveld,Mario Boccadoro,Kenneth C. Anderson,Paul G. Richardson,William I. Bensinger,Hans Erik Johnsen,Nicolaus Kroeger,Gösta Gahrton,P. Leif Bergsagel,David H. Vesole,Hermann Einsele,Sundar Jagannath,Ruben Niesvizky,Brian G.M. Durie,Jesús F. San Miguel,Sagar Lonial +25 more
TL;DR: The role of high-dose therapy followed by autologous stem cell transplantation (ASCT) in the treatment of multiple myeloma continues to evolve in the novel agent era and important perspectives and guidance are provided on the major issues surrounding the optimal current management of younger, transplantation-eligible MM patients.
Journal ArticleDOI
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
Aurore Perrot,Valérie Lauwers-Cances,Jill Corre,Jill Corre,Nelly Robillard,Cyrille Hulin,Marie-Lorraine Chretien,Thomas Dejoie,Sabrina Maheo,Sabrina Maheo,Anne-Marie Stoppa,Brigitte Pegourie,Lionel Karlin,Laurent Garderet,Bertrand Arnulf,Chantal Doyen,Nathalie Meuleman,Bruno Royer,Jean-Richard Eveillard,Lotfi Benboubker,Mamoun Dib,Olivier Decaux,Arnaud Jaccard,Karim Belhadj,Sabine Brechignac,Brigitte Kolb,Cecile Fohrer,Mohamad Mohty,Margaret Macro,Paul G. Richardson,Victoria Carlton,Martin Moorhead,Thomas D. Willis,Malek Faham,Kenneth C. Anderson,Jean-Luc Harousseau,Xavier Leleu,Thierry Facon,Philippe Moreau,Michel Attal,Hervé Avet-Loiseau,Hervé Avet-Loiseau,Nikhil C. Munshi +42 more
TL;DR: The findings confirm the value of MRD status, as determined by NGS, as a prognostic biomarker in multiple myeloma, and suggest that this approach could be used to adapt treatment strategies in future clinical trials.
Journal ArticleDOI
Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma
Philippe Moreau,Hervé Avet-Loiseau,Thierry Facon,Michel Attal,Mourad Tiab,Cyrille Hulin,Chantal Doyen,Laurent Garderet,Edouard Randriamalala,Carla Araujo,Gérard Lepeu,Gerald Marit,Denis Caillot,Martine Escoffre,Bruno Lioure,Lotfi Benboubker,Brigitte Pegourie,Brigitte Kolb,Anne-Marie Stoppa,Jean-Gabriel Fuzibet,Olivier Decaux,Mamoun Dib,Christian Berthou,Carine Chaleteix,Catherine Sebban,Catherine Traullé,Jean Fontan,Marc Wetterwald,Pascal Lenain,Claire Mathiot,Jean-Luc Harousseau +30 more
TL;DR: The Intergroupe Francophone du Myelome conducted a randomized trial to compare bortezomib-dexamethasone (VD) as induction before high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) in patients with multiple myeloma.